Biliary tract - Ductus biliaris | Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors

excerpt from an edition:

A T L A S - Interpretable prognosis for susceptibility to active anti-cancer molecular forms, based on amides/carboxylic acids - hydrolysis derivatives of natural nitrile glycosides, of transcriptome cell lines inherent in tumors /Second supplemented edition/ - DOI: 10.5281/zenodo.13777292 | ISBN: 978-619-91534-6-8

--------------

From the data on the interpretable prognosis of sensitivity to active anti-cancer molecular forms (p.10 form the ATLAS) of transcriptome cell lines inherent in tumors in the Biliary tract (a. & b.), it is concluded that:

- some of the main potential medicines:

(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butanamide and .../butanoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-3-methylbutanamide and .../butanoic acid ,

(R)-3-methyl-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)but-3-enamide and .../enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-3-methylbut-3-enamide and .../enoic acid ,

(Z)-2-((2S,3R,4S,6R)-2,3-dihydroxy-4-methoxy-6-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexylidene)acetamide and .../acetic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (E)-2-((2S,3R,4S,6R)-2,3,6-trihydroxy-4-methoxycyclohexylidene)acetamide and .../acetic acid ,

((2R,3S,4S,5R,6R)-6-(((2R,3S)-4-amino-3-methyl-4-oxobutan-2-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl (2S,3R)-2-ethyl-2,3-dihydroxybutanoate and (2S,3R)-3-(((2R,3R,4S,5S,6R)-6-((((2S,3R)-2-ethyl-2,3-dihydroxybutanoyl)oxy)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2-methylbutanoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (2S,3R)-3-hydroxy-2-methylbutanamide and .../butanoic acid ,

(1S,4R)-4-carbamoyl-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclopent-2-en-1-yl sulfate and (1S,4R)-4-carboxy-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclopent-2-en-1-yl sulfate in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (1R,4R)-4-carbamoyl-4-hydroxycyclopent-2-en-1-yl sulfate and (1R,4R)-4-carboxy-4-hydroxycyclopent-2-en-1-yl sulfate ,

the rest ACCF can be found in the file and the ATLAS ;

- certain medicines for duplication of treatment and/or replacement for medical reasons:

(R)-2-(hydroxymethyl)-2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butanamide and .../butanoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (R)-2-hydroxy-2-(hydroxymethyl)butanamide and .../butanoic acid ,

(Z)-4-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)but-2-enamide and .../enoic acid in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (Z)-4-hydroxybut-2-enamide and .../enoic acid ,

(S)-4-amino-2-methylene-4-oxo-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butyl sulfate and 2-((S)-carboxy(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)allyl sulfate in stoichiometric ratio by mass 4.87:1 is released inside the cancer cell (S)-4-amino-3-hydroxy-2-methylene-4-oxobutyl sulfate and (S)-2-(carboxy(hydroxy)methyl)allyl sulfate ,

the rest ACCF can be found in the file and the ATLAS.

-------

Important! Do not forget to comply with the current clinical control.